Phase 2 Lung cancer trials recruiting now

All Lung cancer trials, every phase

Other phases for Lung cancer

Phase 2 Lung cancer trials

• 'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)
  NCT04375904 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
  NCT07189871 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
  NCT06503146 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
  NCT07508852 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A 2-part Phase 1/2 Open-label Trial on ODM-212
  NCT07563738 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  NCT07227597 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 52 locations
• A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
  NCT07286149 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
  NCT05913089 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 10 locations
• A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
  NCT06892548 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 91 locations
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
  NCT07070232 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 76 locations
• A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
  NCT06496490 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 25 locations
• A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
  NCT07367529 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 38 locations
• A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
  NCT06581419 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
  NCT07111520 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 85 locations
• A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
  NCT07231068 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
  NCT07439094 · Phase: Phase 1, Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
  NCT07629960 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
  NCT07354711 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  NCT07459751 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
  NCT07559786 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
  NCT07632235 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
  NCT05242965 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
  NCT07636785 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
  NCT06956690 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
  NCT06427941 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 49 locations
• A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
  NCT07491497 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
  NCT05394831 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
  NCT06616766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
  NCT05150691 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 204 locations
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 107 locations
• A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
  NCT07292168 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase 2 Clinical Study of ABSK061 and ABSK043
  NCT06632262 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
  NCT06668103 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
  NCT07164170 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
  NCT07133425 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
  NCT07562581 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
  NCT07659782 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
  NCT06695845 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 56 locations
• A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
  NCT05902988 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
  NCT06380816 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
  NCT07309276 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
  NCT07241767 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
  NCT07308106 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
  NCT07253142 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
  NCT06907615 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
  NCT06295432 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
  NCT07489716 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
  NCT06769295 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
  NCT07669779 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase II Study of GC101 in NSCLC
  NCT07560111 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Phase II Study of SKB571 in Patients With Lung Cancer
  NCT07230405 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
  NCT07171606 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
  NCT07548060 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
  NCT07269782 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
  NCT07444437 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
  NCT05837052 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
  NCT06306456 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
  NCT06848699 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
  NCT05543330 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
  NCT05910827 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
  NCT07362940 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
  NCT06177925 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
  NCT06962865 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 34 locations
• A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)
  NCT05613413 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
  NCT06996782 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 103 locations
• A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
  NCT07082179 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma
  NCT07063888 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy
  NCT06467500 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07373964 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
  NCT06421298 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules
  NCT04905056 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
  NCT06156527 · Phase: Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 5 locations
• A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
  NCT07365319 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
  NCT06822543 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
  NCT06228326 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
  NCT06424899 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
  NCT06244771 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
  NCT07103395 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
  NCT07603856 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
  NCT07034391 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
  NCT05893888 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 4 locations
• A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
  NCT05789082 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 71 locations
• A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT07680764 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 71 locations
• A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
  NCT07623356 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
  NCT07287995 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
  NCT07488676 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
  NCT06057935 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
  NCT06483282 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
  NCT06775275 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
  NCT07465757 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
  NCT06095505 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
  NCT07227025 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT06667076 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 203 locations
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  NCT05498428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 110 locations
• A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
  NCT06706076 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations
• A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
  NCT07323732 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
  NCT06951464 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Showing 100 of 770 recruiting trials.

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.